Cisplatin for Lung Cancer: 91 Real Stories

Stage III Pulmonary Sarcomatoid Carcinoma With Major Response to Neoadjuvant Treatment

Patient Info: Anonymized, male, 50s | Stage III

Biomarkers: PIK3CA mutation; TP53 mutation; PD-L1 TPS 5%

No recurrence was detected for more than 29 months after surgery.

PubMed CentralRead more →

Stage III Pulmonary Sarcomatoid Carcinoma With Major Response and No Recurrence

Patient Info: Anonymized, male, 50s | Stage III

Biomarkers: NRAS mutation; TP53 mutation; PD-L1 TPS 60%

No recurrence was detected for more than 27 months after surgery.

PubMed CentralRead more →

Stage III Pulmonary Sarcomatoid Carcinoma Treated With Neoadjuvant Immunochemotherapy and Surgery

Patient Info: Anonymized, male, 60s | Stage III

Biomarkers: TP53 mutation; PD-L1 TPS 40%

No recurrence was detected for more than 30 months after surgery.

PubMed CentralRead more →

Lung Adenocarcinoma With Immune-Related Abdominal Inflammation and Later Bone Progression

Patient Info: Anonymized, male | Stage IV

Biomarkers: PD-L1 30%; KRAS G13X mutation; EGFR/ALK/ROS1 negative

Metastatic Site: bone

After several periods of response or stability, lymph-node progression recurred and bone progression was documented in July 2024. Another treatment line was being planned.

PubMed CentralRead more →

Recurrent Lung Adenocarcinoma Complicated by a Tracheopericardial Fistula

Patient Info: Anonymized, male, 70+ | Stage II

Biomarkers: No gene mutations identified on postoperative testing

He died during the June 2024 admission, about 7½ years after his November 2016 lung-cancer diagnosis, after massive hemoptysis occurred in the setting of a tracheopericardial fistula and recurrent cancer.

PubMed CentralRead more →

Two Severe Kidney Injuries After Lung Cancer Immunotherapy

Patient Info: Anonymized, Male, 70+

The lung cancer remained stable without further anticancer treatment, while the patient remained dependent on hemodialysis after the second kidney injury and continued tapering prednisolone.

PubMed CentralRead more →

Stage 4 lung LCNEC: major response to chemotherapy plus immunotherapy

Patient Info: Anonymized, Male, 40s | Stage IV

Biomarkers: Large-cell neuroendocrine lung cancer markers were positive. PD-L1 was negative

Metastatic Site: left adrenal gland

By July 2024, PET-CT showed complete metabolic response of the adrenal metastasis, no visible adrenal disease, no pulmonary recurrence, and no distant metastasis after immunochemotherapy, lobectomy, adjuvant therapy, and serplulimab maintenance.

PubMed CentralRead more →

Stage 3 lung cancer: complete response to chemo and immunotherapy

Patient Info: Anonymized, Male, 70+ | Stage III

Biomarkers: Tumor markers were normal during mesorectal nodule workup; lung molecular biomarkers were not reported.

No radiologic NSCLC recurrence was detected during 16 months of follow-up after complete response to cisplatin/docetaxel chemoradiation plus 1 year of durvalumab; the suspicious mesorectal nodule proved to be a benign organized thrombus.

PubMed CentralRead more →

Stage IIIA NSCLC: recurrence-free after surgery, adjuvant chemotherapy, and one atezolizumab dose

Patient Info: Anonymized, Female, 60s | Stage III

Biomarkers: PD-L1 expression 20% by 22C3 assay

She remained free of lung-cancer recurrence for more than 1 year after surgery and adjuvant cisplatin/vinorelbine; atezolizumab was stopped after 1 dose because of severe immune-related toxicities that improved with steroid and immunoglobulin treatment.

PubMed CentralRead more →

EGFR-mutant lung adenocarcinoma in Li-Fraumeni syndrome: relapse-free after lobectomy and chemotherapy

Patient Info: Anonymized, Female, 40s

Biomarkers: Lung tumor had EGFR exon 19 deletion. Germline TP53 variant was consistent with Li-Fraumeni syndrome; prior breast cancers were HER2 positive.

As of July 2024, she was free of relapse 2 years after left inferior lobectomy and pemetrexed/cisplatin for EGFR exon 19 deletion lung adenocarcinoma.

PubMed CentralRead more →

First reported case of a severe immune reaction (cytokine release syndrome) from tislelizumab

Patient Info: Anonymized, Male, 70+ | Stage IV

Metastatic Site: pleura (malignant pleural effusion)

The cytokine release syndrome initially improved with high-dose steroids, but he developed severe ventilator-associated pneumonia during the steroid taper and died.

PubMed CentralRead more →

Rare small cell lung cancer subtype removed by surgery

Patient Info: Anonymized, Male

Biomarkers: Cytokeratin-negative; focal TTF-1-positive; Napsin A-negative; electron microscopy showed neurosecretory granules; EWSR1 and SS18 rearrangement testing negative

Follow-up scans found no residual, recurrent or metastatic lung cancer, and he was doing well.

PubMed CentralRead more →

Severe kidney injury during pembrolizumab-based treatment for lung adenocarcinoma

Patient Info: Anonymized, Male, 70+

Kidney function stabilized during six months of follow-up, and he later began a modified cancer regimen containing SAR408701.

PubMed CentralRead more →

Early kidney injury after first-line treatment for lung adenocarcinoma

Patient Info: Anonymized, Male, 70+

Kidney function improved after a short prednisone course, and he later continued cancer care with carboplatin and nab-paclitaxel.

PubMed CentralRead more →

Severe immune-related kidney and lung toxicity during treatment for lung adenocarcinoma

Patient Info: Anonymized, Male, 60s

Corticosteroid treatment returned kidney function to baseline, but worsening immune-related lung toxicity led him and his family to choose palliative care.

PubMed CentralRead more →

Kidney inflammation during maintenance treatment for lung adenocarcinoma

Patient Info: Anonymized, Male, 50s

Kidney function remained stable during three months of follow-up after prednisone was started for biopsy-confirmed acute tubulointerstitial nephritis.

PubMed CentralRead more →

ECMO-Supported Airway Tumor Removal for Squamous Lung Cancer

Patient Info: Anonymized, Male, 60s

Bronchoscopy at three months found no malignancy, and he remained disease-free one year after hospital discharge.

PubMed CentralRead more →

Immunotherapy and surgery for adenosquamous lung cancer with brain metastases

Patient Info: Anonymized, Female, 70+

Biomarkers: PD-L1 positive; no actionable mutations on next-generation sequencing.

After chemotherapy, 19 cycles of pembrolizumab, and right middle lobectomy, she was off immunotherapy and under observation in remission.

PubMed CentralRead more →

Severe headache during chemotherapy for small-cell lung cancer

Patient Info: Anonymized, Male, 50s

After the regimen change, he completed five chemotherapy cycles, remained free of severe headache, and had improvement in chest pain, cough, and breathing.

PubMed CentralRead more →

Low-dose intrapleural therapy relieved a complex malignant pleural effusion

Patient Info: Anonymized, Female, Under 40 | Stage Metastatic/Advanced

Biomarkers: EGFR mutation-negative; ALK alteration-negative; ROS1 alteration-negative.

Metastatic Site: pleura; adrenal gland; bone

The lung cancer had progressed after initial chemotherapy, but rescue treatment of the infected loculated pleural effusion drained 2,000 mL, resolved the collection, and improved her breathing and fever.

PubMed CentralRead more →

Metastatic NRG1-Fusion Lung Cancer Responding to Long-Term Afatinib

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Biomarkers: CD74-NRG1 fusion

Metastatic Site: lungs

As of February 2020, she remained on afatinib 30 mg daily with an ongoing partial response after 27 months.

PubMed CentralRead more →

Recurrent NRG1-Fusion Lung Cancer After Surgery and Immunotherapy

Patient Info: Anonymized, Male, 60s | Stage Metastatic/Advanced

Biomarkers: SDC4-NRG1 fusion

He chose no further treatment after rapid progression on afatinib and died shortly afterward in hospice.

PubMed CentralRead more →

Stage IV Mucinous Lung Cancer Treated With Afatinib and Surgery

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: CD74-NRG1 fusion; ALK/ROS1/EGFR/BRAF/KRAS/MET/HER2 wild type; PD-L1 initially not expressed and later 0%-20%

Metastatic Site: bilateral lungs|bone|right adrenal gland

She was alive and receiving treatment after bone and right-adrenal progression at the latest follow-up.

PubMed CentralRead more →

Recurrent Mucinous Lung Cancer With Dose-Dependent Afatinib Responses

Patient Info: Anonymized, Female, Under 40 | Stage Metastatic/Advanced

Biomarkers: SDC4-NRG1 fusion; PD-L1 not expressed; low tumor mutation burden

Metastatic Site: bilateral lungs

She had progressive lung disease after several targeted-treatment attempts and was receiving paclitaxel with bevacizumab as of February 2020.

PubMed CentralRead more →